Get Level 2

If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Nominated Adviser Status

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.845    -0.205 (-5.06%)
Bid:
3.70
Ask:
3.995
Spread: 0.295 (7.973%)
Market Cap: £23.99m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Nominated Adviser Status

1 Nov 2018 13:38

RNS Number : 0704G
Immupharma PLC
01 November 2018
 

 

1 November 2018

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Nominated Adviser Status

 

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

 

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled.

 

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.co.uk)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations 

+ 44 (0) 7721 413496

 

Northland Capital Partners Limited (NOMAD & Joint Broker)David Hignell, Dugald Carlean, Jamie Spotswood, Corporate FinanceRob Rees, Corporate Broking

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

Chris Coleman

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0)20 3861 6625

 

 

 

 

+44 (0) 20 3815 8880

 

 

+44 (0) 1483 413500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGGQWGUPRGWG
234567891011
Date   Source Headline
28th Jun 20107:00 amRNSPresentation at the International Congress
23rd Jun 20107:40 amRNSReplacement of Development release
23rd Jun 20107:00 amRNSCephalon initiates critical steps in development
17th Jun 201012:02 pmRNSResult of AGM
10th Jun 201010:55 amRNSAnnual Report and Accounts
19th May 20107:01 amRNSInitiation Of Phase I/IIA Studies In Cancer
19th May 20107:00 amRNSPreliminary Results
8th Apr 20109:26 amRNSBest Drug Development Company in Europe Award
5th Jan 20103:00 pmRNSAdditional Listing
5th Jan 20107:00 amRNSING take 4% stake in ImmuPharma plc
3rd Dec 20097:00 amRNSR&D Symposium at the CNRS in Paris
19th Nov 20097:00 amRNSPositive Final Lupuzor Trial Results
19th Oct 200910:31 amRNS'Best Technology 2009' Award at the AIM Awards
9th Oct 200910:14 amRNSAppointment of Joint Broker
29th Sep 20097:00 amRNSInterim Results
21st Sep 20099:55 amRNS8th Annual Bio Investor Forum
17th Sep 20097:00 amRNSJMP Healthcare Focus Conference
24th Jul 200912:12 pmRNSResult of AGM
23rd Jul 20094:17 pmRNSDirectors' Dealings
30th Jun 20097:00 amRNSAnnual Report and Accounts
24th Jun 20097:00 amRNSPreliminary Results
17th Jun 20097:00 amRNSPiper Jaffray Europe Conference
23rd Mar 20097:00 amRNSDirectors' Dealings
4th Feb 200912:32 pmRNSShare Options
2nd Feb 20092:33 pmRNSCephalon license exercise
30th Jan 20097:00 amRNSSuccessful trial results
22nd Dec 200812:00 pmRNSfurther instalment of grant
25th Nov 20087:00 amRNSOption Agreement with Cephalon
12th Nov 20087:00 amRNSGrant Award
21st Oct 20089:31 amRNSPatents Granted
17th Oct 20084:22 pmRNSAdditional Listing and Total Voting Rights
25th Sep 20087:00 amRNSInterim Results
5th Aug 20083:44 pmRNSAGM Result
10th Jul 20087:00 amRNSSecond Placing
2nd Jul 20087:30 amRNSToxicology study
2nd Jul 20087:00 amRNSFund Raising
30th Jun 20083:00 pmRNSAnnual Report and Accounts
20th May 20087:00 amRNSPre-clinical Data
13th May 20086:00 amRNSTrademark Approval
8th May 20087:00 amRNSPreliminary Results
26th Feb 20087:00 amRNSPhase IIb Trial of IPP-201101
8th Jan 20087:00 amRNSNovel Drug Candidate
18th Dec 200712:51 pmRNSDirectors' Dealings
6th Dec 20077:01 amRNSInitiation of Phase IIb trial
16th Nov 200712:28 pmRNSAppointment of Nomad
28th Sep 20077:02 amRNSInterim Results
22nd Aug 20077:00 amRNSCompound Discovery
20th Aug 200710:17 amRNSAIM Rule 26
13th Aug 20074:17 pmRNSDirectors' Dealing
6th Aug 20072:40 pmRNSGrant of Options
234567891011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
ROL
ROL.L
LSE
0.00%
RDSA
RDSA.L
LSE
0.00%
IND
IND.L
LSE
0.00%
ZAM
Zambeef Prod.
LSE
3.19%
BGHL
Boussard Eur
LSE
0.00%
Trending
GGP
Greatland Resources
LSE
-6.98%
CPI
Capita
LSE
-0.89%
PREM
Premier African Minerals
LSE
3.03%
AVCT
Avacta Group
LSE
-1.42%
GST
GSTechnologies
LSE
0.00%